Hepatocyte growth factor: Molecular biomarker and player in cardioprotection and cardiovascular regeneration

Summary

The liver possesses impressive regenerative capacities. Grafts of embryonic liver explants and liver explant-conditioned media have been shown to enhance the mitotic activity of hepatocytes. Hepatocyte growth factor (HGF), also named scatter factor (SF), has been identified as a primary candidate in promoting and regulating liver regeneration. Although initially thought to be a liver-specific mitogen, HGF was later reported to have mitogenic, motogenic, morphogenic, and anti-apoptotic activities in various cell types. By promoting angiogenesis and inhibiting apoptosis, endogenous HGF may play an important role in cardioprotection as well as in the regeneration of endothelial cells and cardiomyocytes after myocardial infarction. Since serum concentration of HGF increases in the early phase of myocardial infarction and in heart failure, HGF may also play a key role as a prognostic and diagnostic biomarker of cardiovascular disease. Here we discuss the role of HGF as a biomarker and mediator in cardioprotection and cardiovascular regeneration.

Keywords

Hepatocyte growth factor - myocardial infarction - heart failure - biomarker - adult stem cells - cardioprotection

• References

• 1 Lundberg JJ, Mollgard K. Mitotic activity in adult rat brain induced by implantation of pieces of fetal rat brain and liver. Neurosci Lett 1979; 13: 265-270.
• 2 Gherardi E, Sandin S, Petoukhov MV. et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci USA 2006; 103: 4046-4051.
• 3 Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984; 122: 1450-1459.
• 4 Schmidt C, Bladt F, Goedecke S. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995; 373: 699-702.
• 5 Nakamura T, Nishizawa T, Hagiya M. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989; 342: 440-443.
• 6 Montesano R, Schaller G, Orci L. Induction of epithelial tubular morphogenesis in vitro by fibroblast-derived soluble factors. Cell 1991; 66: 697-711.
• 7 Lokker NA, Mark MR, Luis EA. et al. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J 1992; 11: 2503-2510.
• 8 Balkovetz DF, Lipschutz JH. Hepatocyte growth factor and the kidney: it is not just for the liver. Int Rev Cytol 1999; 186: 225-260.
• 9 Matsumori A, Furukawa Y, Hashimoto T. et al. Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction. Biochem Biophys Res Commun 1996; 221: 391-395.
• 10 Lamblin N, Susen S, Dagorn J. et al. Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. Am Heart J 2005; 150: 137-143.
• 11 Rychli K, Richter B, Hohensinner PJ. et al. Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart 2011; 97: 1158-1163.
• 12 Birchmeier C, Birchmeier W, Gherardi E. et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 04: 915-925.
• 13 Bottaro DP, Rubin JS, Faletto DL. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251: 802-804.
• 14 Huh CG, Factor VM, Sanchez A. et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004; 101: 4477-4482.
• 15 Morishita R, Aoki M, Hashiya N. et al. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther 2004; 04: 199-206.
• 16 Borowiak M, Garratt AN, Wustefeld T. et al. Met provides essential signals for liver regeneration. Proc Natl Acad Sci USA 2004; 101: 10608-10613.
• 17 Chmielowiec J, Borowiak M, Morkel M. et al. c-Met is essential for wound healing in the skin. J Cell Biol 2007; 177: 151-162.
• 18 Nakamura T, Mizuno S, Matsumoto K. et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000; 106: 1511-1519.
• 19 Ono K, Matsumori A, Shioi T. et al. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997; 95: 2552-2558.
• 20 Ueda H, Nakamura T, Matsumoto K. et al. A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats. Cardiovasc Res 2001; 51: 41-50.
• 21 Aoki M, Morishita R, Taniyama Y. et al. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: upregulation of essential transcription factor for angiogenesis, ets. Gene Ther 2000; 07: 417-427.
• 22 Taniyama Y, Morishita R, Nakagami H. et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000; 102: 246-252.
• 23 Rappolee DA, Iyer A, Patel Y. Hepatocyte growth factor and its receptor are expressed in cardiac myocytes during early cardiogenesis. Circ Res 1996; 78: 1028-1036.
• 24 Oh SH, Miyazaki M, Kouchi H. et al. Hepatocyte growth factor induces differentiation of adult rat bone marrow cells into a hepatocyte lineage in vitro. Biochem Biophys Res Commun 2000; 279: 500-504.
• 25 Forte G, Minieri M, Cossa P. et al. Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 2006; 24: 23-33.
• 26 Urbanek K, Rota M, Cascapera S. et al. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 2005; 97: 663-673.
• 27 Madonna R, Rokosh G, De Caterina R. et al. Hepatocyte growth factor/Met gene transfer in cardiac stem cells--potential for cardiac repair. Basic Res Cardiol 2010; 105: 443-452.
• 28 Roggia C, Ukena C, Bohm M. et al. Hepatocyte growth factor (HGF) enhances cardiac commitment of differentiating embryonic stem cells by activating PI3 kinase. Exp Cell Res 2007; 313: 921-930.
• 29 Guo Y, He J, Wu J. et al. Locally overexpressing hepatocyte growth factor prevents post-ischemic heart failure by inhibition of apoptosis via calcineurin-mediated pathway and angiogenesis. Arch Med Res 2008; 39: 179-188.
• 30 Zhu XY, Zhang XZ, Xu L. et al. Transplantation of adipose-derived stem cells over-expressing hHGF into cardiac tissue. Biochem Biophys Res Commun 2009; 379: 1084-1090.
• 31 Poppe A, Golsong P, Blumenthal B. et al. Hepatocyte Growth Factor-Transfected Skeletal Myoblasts to Limit the Development of Postinfarction Heart Failure. Artif Organs. 2011 epub ahead of print.
• 32 Rehman J, Traktuev D, Li J. et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109: 1292-1298.
• 33 Nakagami H, Maeda K, Morishita R. et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 2005; 25: 2542-2547.
• 34 Cai L, Johnstone BH, Cook TG. et al. Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells 2007; 25: 3234-3243.
• 35 Matsumori A, Takano H, Obata JE. et al. Circulating hepatocyte growth factor as a diagnostic marker of thrombus formation in patients with cerebral infarction. Circ J 2002; 66: 216-218.
• 36 Zhu Y, Hojo Y, Ikeda U. et al. Production of hepatocyte growth factor during acute myocardial infarction. Heart 2000; 83: 450-455.
• 37 Beohar N, Rapp J, Pandya S. et al. Rebuilding the damaged heart: the potential of cytokines and growth factors in the treatment of ischemic heart disease. J Am Coll Cardiol 2010; 56: 1287-1297.
• 38 Chowdhury M, Ghosh J, Slevin M. et al. A comparative study of carotid atherosclerotic plaque microvessel density and angiogenic growth factor expression in symptomatic versus asymptomatic patients. Eur J Vasc Endovasc Surg 2010; 39: 388-395.
• 39 Morishita R, Makino H, Aoki M. et al. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol 2011; 31: 713-720.
• 40 Powell RJ, Simons M, Mendelsohn FO. et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118: 58-65.
• 41 Banquet S, Gomez E, Nicol L. et al. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 2011; 124: 1059-1069.
• 42 Epstein SE, Kornowski R, Fuchs S. et al. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation 2001; 104: 115-119.